Phage Safety Cohort Study
Launched by HOSPICES CIVILS DE LYON · Nov 25, 2020
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The Phage Safety Cohort Study is looking into the safety of using bacteriophages, which are viruses that can kill bacteria, to treat serious infections, especially in patients with prosthetic joint infections. This study is important because there is very little information available about the potential side effects of using phage therapy. The researchers are currently recruiting participants who are 18 years or older, weigh at least 46 kg, and are receiving treatment for a serious infection at a specific center in Lyon.
If you or a loved one is eligible and decides to join the study, you will be closely monitored for any unwanted effects related to the phage treatment. It’s essential to note that individuals under guardianship or those who are pregnant or breastfeeding cannot participate. This study aims to improve our understanding of how safe phage therapy is, helping to pave the way for future treatments for severe infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient 18 years of age or older with a serious infection treated at CRIOAc Lyon by phage therapy
- • Patient who did not object to participating in the study
- • Patients ayant un poids minimum de 46kg
- Exclusion Criteria:
- • Patients under guardianship/curatorship
- • Patients deprived of liberty
- • Pregnant or breastfeeding women
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials